[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2855 Introduced in House (IH)]
<DOC>
116th CONGRESS
1st Session
H. R. 2855
To deem the application submitted by Jaci Hermstad to the Food and Drug
Administration for compassionate use of the gene therapy antisense
oligonucleotides to be approved.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 20, 2019
Mr. King of Iowa introduced the following bill; which was referred to
the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To deem the application submitted by Jaci Hermstad to the Food and Drug
Administration for compassionate use of the gene therapy antisense
oligonucleotides to be approved.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. DEEMED APPROVAL OF APPLICATION FOR COMPASSIONATE USE OF THE
GENE THERAPY ANTISENSE OLIGONUCLEOTIDES.
Notwithstanding the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
301 et seq.) or any other provision of law, the application submitted
by Jaci Hermstad to the Food and Drug Administration for compassionate
use of the gene therapy antisense oligonucleotides is deemed to be
approved.
<all>
To deem the application submitted by Jaci Hermstad to the Food and Drug Administration for compassionate use of the gene therapy antisense oligonucleotides to be approved.
#2855 | HR Congress #116
Subjects: Private Legislation
Last Action: Referred to the Subcommittee on Health. (5/21/2019)
Bill Text Source: Congress.gov
Summary and Impacts
Original Text